Vertex's Shocking Decline Hurts Investors


In this video, health care analyst David Williamson discusses Vertex Pharmaceuticals' recent third-quarter results, breaking down the company's surprising loss and estimate miss, along with the future of its lead drug, Incivek. Watch and find out what investors should take away from these disappointing results.

While you can certainly make huge gains in biotech and pharmaceuticals, the best investing approach is to choose great companies and stick with them for the long term. In our free report "3 Stocks That Will Help You Retire Rich," we name stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.

The article Vertex's Shocking Decline Hurts Investors originally appeared on

David Williamson owns shares of Johnson & Johnson. Follow him on Twitter @MotleyDavid. The Motley Fool owns shares of GlaxoSmithKline and Johnson & Johnson. Motley Fool newsletter services recommend GlaxoSmithKline, Johnson & Johnson, and Vertex Pharmaceuticals. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Originally published